The full article is available here:
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3660127/
In the paragraph about synovial sarcoma, 2 promising trials are mentioned. The phase 1 results of the Apo2L/Trail trial are here:
http://jco.ascopubs.org/content/28/17/2839.long
In this trial, there was a patient with synovial sarcoma who had a serious adverse event because his tumor actually responded too quickly to the drug. Here is an excerpt from the publication:
"Two patients experienced SAEs apparently related to rapid tumor involution. The first was a 42-year-old male with high-grade synovial sarcoma of the gastric wall who had undergone partial gastrectomy followed by multiple courses of chemotherapy, including ifosphamide/mesna, paclitaxel, STA-4783, and glufosfamide/gemcitabine. Following the first cycle of rhApo2L/TRAIL on study day 21, he was hospitalized for an intra-abdominal hemorrhage that arose from bleeding into and rupture of one of the abdominal tumors. Emergency surgery revealed extensive central necrosis of the tumors and hemorrhage. The postoperative course was complicated by a jejunal perforation, requiring a second emergency surgery."
The other trial mentioned is cediranib which is similar to votrient. Results of phase 1 are here: